New hope for brain cancer: experimental combo targets glioblastoma

NCT ID NCT04752813

Ongoing Disease control Sponsor: BPGbio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the experimental drug BPM31510 (with vitamin K1) to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 50 adults with this aggressive brain tumor will receive the combination. The goal is to see if the treatment improves progression-free survival and overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Inova

Fairfax, Virginia, 22037, United States
Mount Sinai Hospital

New York, New York, 10029, United States
Sansum Clinic

Santa Barbara, California, 93105, United States
Stanford University Cancer Center

Palo Alto, California, 94305, United States
Texas Oncology

Austin, Texas, 78705, United States
UT Health San Antonio Mays Cancer Center

San Antonio, Texas, 78229, United States
Valley Health

Ridgewood, New Jersey, 07450, United States
Virginia Cancer Specialists

Fairfax, Virginia, 22031, United States
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.